AC
ACON.US Aclarion Inc
- Market cap
- USD 4.62M
- P/E
- -
- P/B
- 0.32x
- ROE
- -74.1%
- Dividend yield
- 117,486.39%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ACON.US undervalued?
Graham numberThe Graham number of Aclarion Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aclarion Inc fundamental analysis
No fundamental analysis for Aclarion Inc yet.
Aclarion Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aclarion Inc
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequen…
Full company profileAclarion Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aclarion Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 26.9K | 48.7K | 60.3K | 60.4K | 75.4K | 45.7K | 75.7K | 107K |
| Gross Profit | -36.3K | -17.6K | -8.88K | -4.85K | -324.00 | -84.0K | -221K | -45.4K |
| Operating Income | -4.01M | -4.48M | -2.95M | -5.56M | -4.88M | -5.51M | -7.05M | -11.5M |
| EBITDA | -3.84M | -4.28M | -4.29M | -5.42M | -4.14M | -6.26M | -7.01M | -10.7M |
| Net Income | -4.02M | -4.64M | -4.95M | -7.07M | -4.91M | -6.99M | -7.23M | -11.0M |
| EPS | -80,385 | -92,705 | -99,006 | -168,300 | -79,216 | -7,416 | -14 | -3.95 |
| Balance Sheet | ||||||||
| Total Assets | 1.43M | 1.29M | 1.89M | 2.91M | 2.46M | 2.12M | 13.7M | 15.8M |
| Total Liabilities | 3.13M | 8.38M | 7.62M | 689K | 3.19M | 1.15M | 837K | 1.03M |
| Shareholders' Equity | -1.70M | -7.08M | -5.73M | 2.23M | -728K | 970K | 12.8M | 14.8M |
| Cash & Short-term Investments | 128K | 15.0K | 433K | 1.47M | 1.02M | 454K | 12.0M | 14.2M |
| Total Debt | 516K | 2.38M | 2.00M | 4.64K | 1.13M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -4.17M | -1.79M | -2.35M | -5.31M | -3.65M | -5.27M | -7.16M | -9.76M |
| Capital Expenditure | 267K | 179K | 1.00 | 209K | 120K | 322K | 21.5K | 132K |
| Free Cash Flow | -4.44M | -1.97M | -2.35M | -5.52M | -3.77M | -5.59M | -7.19M | -9.76M |
| Ratios | ||||||||
| ROE | - | - | - | -317.6% | - | -720.9% | -56.4% | -74.1% |
| ROA | -281.0% | -358.8% | -262.0% | -242.5% | -199.7% | -329.3% | -52.9% | -69.2% |
| Net Profit Margin | -14,943.1% | -9,527.3% | -8,210.5% | -11,694.4% | -6,513.4% | -15,293.8% | -9,551.9% | -10,268.6% |
| Debt to Equity | - | - | - | 0.00x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aclarion Inc dividends
- Dividend yield
- 117,486.39%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.43B | 10,197 | - |
| 2024 | USD 59.7K | 63 | - |
| 2023 | - | - | - |
| 2022 | USD 416K | 9,893 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:27 on Mar 28, 2025.
Who owns Aclarion Inc
- Insiders 23.98%
- Institutions 5.35%
- Public & others 70.68%
- Shares outstanding 2.88M
- Free float 2.52M
Top funds holding ACON.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bridgeway Ultra-Small Company | 19.5K | 0.68% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 11.1K | 0.38% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 477.00 | 0.02% | 0.00% | Sep 2026 |
Top institutions holding ACON.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bridgeway Capital Management, LLC | 19.5K | 0.68% | 0.00% | Jun 2026 |
| CapTrust Financial Advisors | 17.1K | 0.59% | +17.17% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 16.0K | 0.56% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 15.4K | 0.53% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 12.1K | 0.42% | -61.15% | Jun 2026 |
| XTX Topco Ltd | 11.0K | 0.38% | 0.00% | Jun 2026 |
| Bank of Montreal | 10.0K | 0.35% | 0.00% | Jun 2026 |
| BMO Capital Markets Corp. | 10.0K | 0.35% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.78K | 0.24% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 5.00K | 0.17% | -85.69% | Jun 2026 |
| UBS Group AG | 1.97K | 0.07% | -79.60% | Jun 2026 |
| Barclays PLC | 283.00 | 0.01% | 0.00% | Jun 2026 |
| Clear Street Group Inc | 103.00 | 0.00% | +3,333.33% | Jun 2026 |
| Wells Fargo & Co | 100.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Dauntless Investment Group, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Danske Bank A/S. | 0.00 | 0.00% | -100.00% | Jun 2026 |
Aclarion Inc company profile
- Company name
- Aclarion Inc
- Ticker
- ACON.US
- Exchange
- USA Stocks
- Listed since
- Apr 22, 2022
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 10
- Fiscal year end
- December
- Address
- 8181 Arista Place, Broomfield, CO, United States, 80021
- Phone
- 833 275 2266
- Website
- aclarion.com
About Aclarion Inc
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Aclarion Inc management
4- Dr. Jeffrey John Thramann M.D.Executive Chairman · born 1965
- Mr. Brent NessCEO, President & Director · born 1967
- Mr. Gregory A. Gould CPAChief Financial Officer · born 1966
- Mr. Ryan BondChief Strategy Officer · born 1972